Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD

In three women with age-related macular degeneration and with visual acuity ranging from 20/30 to 20/200 before they received bilateral intravitreal injection of autologous “stem cells,” blinding complications developed in each of their eyes. Age-related macular degeneration (AMD) is the leading cau...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 376; no. 11; pp. 1047 - 1053
Main Authors: Kuriyan, Ajay E, Albini, Thomas A, Townsend, Justin H, Rodriguez, Marianeli, Pandya, Hemang K, Leonard, Robert E, Parrott, M. Brandon, Rosenfeld, Philip J, Flynn, Harry W, Goldberg, Jeffrey L
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 16.03.2017
Series:Brief Report
Subjects:
Acuity
Adipose tissue
Adipose Tissue - cytology
Adipose Tissue - transplantation
Aged
Aged, 80 and over
Autografts
Blindness - etiology
Bone marrow
Clinical trials
Clinics
Dislocation
Edema
Enzymes
FDA approval
Female
Hemorrhage
Humans
Injection
Injections
Macular degeneration
Macular Degeneration - therapy
Patients
Retina
Retinal Detachment - etiology
Retinopathy
Stem Cell Transplantation - adverse effects
Stem cells
Transplantation, Autologous - adverse effects
Ultrasonic imaging
Vision Disorders - etiology
Visual Acuity
United States > US
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In three women with age-related macular degeneration and with visual acuity ranging from 20/30 to 20/200 before they received bilateral intravitreal injection of autologous “stem cells,” blinding complications developed in each of their eyes. Age-related macular degeneration (AMD) is the leading cause of vision loss in persons older than 75 years of age in the United States. 1 Progressive dysfunction and loss of retinal pigment epithelium cells and photoreceptors lead to poor visual acuity in patients with non-neovascular AMD. 2 The potential role of delivering subretinal human retinal pigment epithelium, photoreceptor cells, or both, differentiated from pluripotent stem cells, to replace the damaged cells in patients with non-neovascular AMD is being investigated in several clinical trials registered by the Food and Drug Administration (FDA) and approved by institutional review boards. 3 As of November 2, 2016, at . . .
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Case Study-2
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1609583